University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital
Search Site | Find a Doctor
Print this page
FONT SIZE
Home > Doctors > Margaret C. Fang

Margaret C. Fang, M.D.

Hospitalist

Dr. Fang is a hospital-based physician and researcher as well as the medical director of the UCSF Anticoagulation Clinic. As a hospitalist, she provides clinical care for patients who are hospitalized at UCSF Medical Center and supervises resident physicians and medical students.

Fang is an associate professor of medicine at UCSF. She completed an internal medicine residency at Beth Israel Deaconess Medical Center in Boston, obtained a master's of public health from Harvard School of Public Health and a general internal medicine fellowship from Massachusetts General Hospital. She joined the UCSF Division of Hospital Medicine in 2003. Her research focuses on cardiovascular epidemiology — addressing the use of anticoagulants in clinical care. Ongoing research projects include: the ATRIA cohort study of atrial fibrillation, the CVRN venous thromboemobolism cohort study and the clarification of optimal anticoagulant through genetics clinical trail of warfarin pharmacogenetics.

More about Margaret C. Fang

Education

Northwestern University Medical School 1998

Residencies

Beth Israel Deaconess Medical Center, Internal Medicine 2001

Fellowships

Massachusetts General Hospital, Internal Medicine 2003

Selected Research and Publications

  1. Shoeb M, Fang MC. Assessing bleeding risk in patients taking anticoagulants. J Thromb Thrombolysis. 2013 Apr; 35(3):312-9.
  2. Quinn GR, Fang MC. Atrial fibrillation: stroke prevention in older adults. Clin Geriatr Med. 2012 Nov; 28(4):617-34.
  3. Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N, Singer DE. Thirty-day mortality after ischemic stroke and intracranial hemorrhage in patients with atrial fibrillation on and off anticoagulants. Stroke. 2012 Jul; 43(7):1795-9.
  4. You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, Fang MC, Hylek EM, Schulman S, Go AS, Hughes M, Spencer FA, Manning WJ, Halperin JL, Lip GY. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb; 141(2 Suppl):e531S-75S.
  5. Fang MC. Selecting the optimal stroke prevention therapy in atrial fibrillation. Ann Intern Med. 2011 Nov 1; 155(9):636-7.
  6. Khanna RR, Karliner LS, Eck M, Vittinghoff E, Koenig CJ, Fang MC. Performance of an online translation tool when applied to patient educational material. J Hosp Med. 2011 Nov; 6(9):519-25.
  7. Rennke S, Fang MC. Hazards of hospitalization: more than just "never events". Arch Intern Med. 2011 Oct 10; 171(18):1653-4.
  8. Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N, Singer DE. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol. 2011 Jul 19; 58(4):395-401.
  9. Fang MC, Maselli J, Lurie JD, Lindenauer PK, Pekow PS, Auerbach AD. Use and outcomes of venous thromboembolism prophylaxis after spinal fusion surgery. J Thromb Haemost. 2011 Jul; 9(7):1318-25.
  10. Fang MC. Anticoagulation in people with atrial fibrillation. BMJ. 2011; 342:d530.
  11. Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N, Singer DE. Warfarin discontinuation after starting warfarin for atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2010 Nov; 3(6):624-31.
  12. Singer DE, Fang MC, Go AS. CHA2DS2-VASc risk scheme: not ready for clinical use. Chest. 2010 Oct; 138(4):1020; author reply 1020-1.
  13. Fang MC, Cutler DM, Rosen AB. Trends in thrombolytic use for ischemic stroke in the United States. J Hosp Med. 2010 Sep; 5(7):406-9.
  14. Sliwka D, Fang MC. Venous thromboembolism prophylaxis in the United States: still room for improvement. J Gen Intern Med. 2010 Jun; 25(6):484-6.
  15. Kneeland PP, Fang MC. Current issues in patient adherence and persistence: focus on anticoagulants for the treatment and prevention of thromboembolism. Patient Prefer Adherence. 2010; 4:51-60.
  16. Mission JF, Kerlan RK, Tan JH, Fang MC. Rates and predictors of plans for inferior vena cava filter retrieval in hospitalized patients. J Gen Intern Med. 2010 Apr; 25(4):321-5.
  17. Singer DE, Fang MC, Go AS. The international normalized ratio range of 2.0 to 3.0 remains appropriate for atrial fibrillation. Arch Intern Med. 2009 Nov 23; 169(21):2032; author reply 2033.
  18. Kneeland PP, Fang MC. Trends in catheter ablation for atrial fibrillation in the United States. J Hosp Med. 2009 Sep; 4(7):E1-5.
  19. Singer DE, Chang Y, Fang MC, Borowsky LH, Pomernacki NK, Udaltsova N, Go AS. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med. 2009 Sep 1; 151(5):297-305.
  20. Singer DE, Chang Y, Fang MC, Borowsky LH, Pomernacki NK, Udaltsova N, Go AS. Should patient characteristics influence target anticoagulation intensity for stroke prevention in nonvalvular atrial fibrillation?: the ATRIA study. Circ Cardiovasc Qual Outcomes. 2009 Jul; 2(4):297-304.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions by logging on to UCSF Profiles.

Home • Terms of Use • Site Map • Contact Us       © 2002 - 2013 The Regents of The University of California